• Revenues from ordinary activities decreased by 16% to US$1,174 thousand
• Loss from ordinary activities after tax increased by 23% to US$42,993 thousand
• Loss for the period attributable to members increased by 22% to US$42,698 thousand

Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) announced its quarterly results for the period ended June 30, 2025. Revenues from ordinary activities decreased by 16% to US$1,174 thousand, while loss from ordinary activities after tax increased by 23% to US$42,993 thousand and loss for the period attributable to members increased by 22% to US$42,698 thousand compared to the prior year period. The company also provided an update on the use of proceeds from its initial public offering, with US$37.6 million used for the ongoing development of DurAVR® THV and the preparation and enrollment of the Pivotal Trial, and US$14.1 million used for net working capital, v2vmedtech expenditure, and other general corporate purposes including the repayment of US$6.4 million of debt. The aggregate amount of payments to related parties and their associates during the second quarter of 2025 was US$640 thousand, which were included in cash flows from operating activities.